BIIB

Biogen shares surged 5.3% to $253.84 driven by positive phase II data from its AMETHYST study for litifilimab in cutaneous lupus erythematosus, with phase III data expected in H1 2027. However, the company's consensus EPS estimate was revised 1.8% lower over the past month, which could limit further price appreciation. Novavax declined 9.3% to $9.99 with its EPS estimate revised down 8.1% over the past month.

Biogen is expected to report Q3 2026 earnings on October 28 with a consensus EPS estimate of $2.04 per share (down 57.6% YoY) and revenues of $2.59 billion (up 2% YoY). With a positive Earnings ESP of +1.81% and Zacks Rank #3 (Hold), the company appears positioned to beat consensus estimates. Biogen has beaten EPS estimates in all four of the last quarters.

Biogen Inc. (BIIB) has demonstrated a consistent pattern of beating earnings estimates, with an average surprise of 19.72% over the last two quarters. The company reported $3.6 per share versus an expected $3.04, and $3.57 versus expected $2.95 in the previous quarter. With a positive Earnings ESP of +2.19% and a Zacks Rank #3 (Hold), analysts suggest another earnings beat is likely when the company reports on October 28, 2026.

Over 200 companies are advancing more than 240 pipeline Alzheimer's disease therapies across various clinical development stages. The market is being driven by an aging population, rising disease prevalence, and the emergence of disease-modifying therapies that enable earlier intervention and biomarker-guided care. Two therapies have recently received FDA approval: KISUNLA (donanemab) from Eli Lilly and LEQEMBI (lecanemab-irmb) from Eisai/Biogen, both targeting amyloid plaques to slow disease progression.

Exelixis is expected to report Q3 2026 earnings of $0.89 per share (up 14.1% YoY) and revenues of $653.06 million (up 9.3% YoY) on October 29. With a positive Earnings ESP of +2.44% and Zacks Rank #3, the company appears positioned to beat consensus estimates. Exelixis has beaten EPS estimates in all four trailing quarters.

Four biotech companies with advanced drug pipelines present potential investment opportunities as their experimental treatments progress through late-stage development and regulatory review. BridgeBio Pharma has three drug candidates under FDA review with decisions expected through May 2027.

Intellia Therapeutics' gene-editing therapy lonvo-z showed 87% reduction in hereditary angioedema attacks. Biogen expects pivotal study results through 2027, while Viking Therapeutics advances obesity treatments in phase III trials. Success depends on regulatory approvals, clinical efficacy, and competitive market positioning.

AbbVie's neuroscience revenues are projected to reach $3.29 billion in Q3 2026, representing approximately 16% year-over-year growth. Key contributors include established drugs Vraylar ($1.08B) and Botox Therapeutic ($1.07B), along with newer products like Vyalev ($283M) and the recently FDA-approved Juvmo. The company faces competition from Biogen and Johnson & Johnson in the neuroscience market.

PBE is a smart beta ETF focused on biotechnology and genome companies with $412.99 million in assets. It has delivered strong year-to-date returns of 16.68% and one-year returns of 36.23%, but carries higher risk with a standard deviation of 20.18%.

The fund charges a 0.59% expense ratio and holds concentrated positions in healthcare stocks like Natera, Illumina, and Biogen. Cheaper alternatives like XBI and IBB are available for investors seeking lower-cost options.

The Invesco Biotechnology & Genome ETF (PBE) is a passively managed fund with $418.99 million in assets, offering exposure to the Healthcare-Biotech sector. With a 0.59% expense ratio and 1.38% dividend yield, it returned 18.51% over the past year but carries higher risk with a beta of 0.70 and 20.16% standard deviation.

The fund holds 33 concentrated positions with top holdings including Royalty Pharma, Gilead Sciences, and Biogen. PBE received a Zacks ETF Rank of 3 (Hold), with larger competitors XBI and IBB offering lower expense ratios.

AbbVie received FDA approval for Juvmo, a once-daily oral treatment for Parkinson's disease launching in October 2026. As the first selective D1/D5 dopamine receptor agonist usable as standalone or combination therapy, Juvmo expands AbbVie's PD portfolio alongside Vyalev and Duopa, with the three therapies expected to generate peak sales above $5 billion. The approval validates AbbVie's $8.7 billion Cerevel Therapeutics acquisition and strengthens its neuroscience segment, which grew 22% year-over-year.